Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,288,116

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,288,116
Title:Methods and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
Abstract: The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipetidyl peptidase IV (DPPIV)] expressed on the surface of metastasizing cancer cells.
Inventor(s): Chen; Wen-Tien (Stony Brook, NY)
Assignee: The Research Foundation of State University of New York (Albany, NY)
Application Number:12/725,036
Patent Claims:1. A capture system for removing cancer cells from a blood fluid containing a mixed population of cancer cells and non-cancer cells, said fluid selected from the group consisting of whole blood, lymph, bone marrow, ascites or a combination thereof, said system comprising a vessel, said vessel comprising a cell-adhesion matrix having a fibrous scaffold coated with at least one adhesion molecule, said fibrous scaffold comprising type I collagen fibers, type III collagen fibers, fibrin, cotton fibers, tissue fragment or plastic fibers, wherein said cancer cells are isolated by incubating the mixed population of cells for a time sufficient to allow said cancer cells to ingest the matrix and isolating said cancer cells that ingest the matrix from cells that do not ingest the matrix.

2. The system of claim 1, further comprising an enzyme for releasing said cancer cells that have ingested the matrix.

3. The system of claim 2, wherein said enzyme comprises collagenase and proteases digesting cell-adhesion matrix.

4. The system of claim 2, wherein said enzyme comprises collagenase and trypsin.

5. The system of claim 1, wherein said system has a level of sensitivity of one viable cancer cell per ml of blood fluid.

6. The system of claim 1, wherein the matrix is labeled with a fluorescent label.

7. The system of claim 1, wherein the matrix is labeled with a radioactive label.

8. The system of claim 1, wherein the matrix is labeled with a color label.

9. The system of claim 1, wherein the matrix is labeled with a cytotoxic compound.

10. The system of claim 1, wherein the at least one adhesion molecule comprises fibronectin.

11. The system of claim 1, wherein the at least one adhesion molecule comprises laminin.

12. The system of claim 1, wherein the at least one adhesion molecule comprises vitronectin.

13. The system of claim 1, further comprising an anticoagulant to prevent said blood fluid from coagulating when said blood fluid is contacted with said matrix.

14. The system of claim 13, wherein said anticoagulant comprises heparin.

15. The system of claim 13, wherein said anticoagulant comprises citrate dextrose.

16. A capture system for removing cancer cells from a blood fluid containing a mixed population of cancer cells and non-cancer cells, said fluid selected from the group consisting of whole blood, lymph, bone marrow, ascites or a combination thereof, said system comprising: (i) a vessel comprising a cell-adhesion matrix having a fibrous scaffold coated with at least one adhesion molecule, said fibrous scaffold comprising type I collagen fibers, type III collagen fibers, fibrin, cotton fibers, tissue fragment or plastic fibers, wherein said cancer cells are isolated by incubating the mixed population of cells for a time sufficient to allow said cancer cells to ingest the matrix and isolating said cancer cells that ingest the matrix from cells that do not ingest the matrix; and (ii) an enzyme for releasing said cancer cells that have ingested the matrix.

17. The system of claim 16, further comprising an anticoagulant to prevent said blood fluid from coagulating when said blood fluid is contacted with said matrix.

18. A capture system for removing cancer cells from a blood fluid containing a mixed population of cancer cells and non-cancer cells, said fluid selected from the group consisting of whole blood, lymph, bone marrow, ascites or a combination thereof, said system comprising: (i) a vessel comprising a cell-adhesion matrix having a fibrous scaffold coated with at least one adhesion molecule, said fibrous scaffold comprising type I collagen fibers, type III collagen fibers, fibrin, cotton fibers, tissue fragment or plastic fibers, wherein said cancer cells are isolated by incubating the mixed population of cells for a time sufficient to allow said cancer cells to ingest the matrix and isolating said cancer cells that ingest the matrix from cells that do not ingest the matrix; (ii) an enzyme for releasing said cancer cells that have ingested the matrix; and (iii) an anticoagulant to prevent said blood fluid from coagulating when said blood fluid is contacted with said matrix.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
McKesson
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.